Italian and Swedish researchers win richest Swiss science prize
This content was published on
2 minutes
SDA-ATS/ac
The Louis-Jeantet Prize for Medicine has been awarded to Antonio Lanzavecchia from the Swiss-Italian University and Christer Betsholtz from the University of Uppsala in Sweden. They will each receive CHF700,000 ($728,221), of which CHF625,000 must be spent on research.
Established in 1986, the prize recognises excellence in European biomedical research. The main fields covered include physiology, biophysics, structural biology, biochemistry, cellular and molecular biology, developmental biology and genetics. Only researchers active in the Council of EuropeExternal link member countries are eligible for the prize.
Lanzavecchia, an immunologist and director of the Institute for Biomedicine Research in Bellinzona, won for his contribution to the understanding of the immune response in humans, and for the detection of antibodies that effectively neutralise various infectious agents.
According to the Louis-Jeantet Foundation, he will use the prize money to continue his research on the characterisation of the mechanism for antibody diversification.
The other winner, Betsholtz, is also the director of the Director of the Karolinska Institute’s Integrated Cardio Metabolic Centre in Stockholm, Sweden. He has been recognised for his fundamental discoveries in vascular biology, including the characterisation of specialised cells – pericytes – and their role in vascular development and permeability. Betsholtz will use the prize money to continue the study of blood vessels in the central nervous system and to better understand their role in normal and pathological processes.
The awards ceremony will take place on April 25 in Geneva. Since its inception, the Louis-Jeantet Prize has been awarded to 90 researchers, including 16 from Switzerland. Ten of them were subsequently awarded the Nobel Prize for Medicine or Chemistry.
The Louis-Jeantet Foundation, created in 1982, is the legacy of Louis Jeantet, a Geneva-based French businessman who made his fortune in the automotive industry. Its mission is to advance medicine and it annually grants around CHF4.2 million to support biomedical research.
Police clear out pro-Palestinian students protesting in Geneva
This content was published on
The police intervened early on Tuesday morning to dislodge the pro-Palestinian students who had been occupying the University of Geneva for almost a week.
New gel developed in Zurich renders alcohol harmless
This content was published on
A newly developed gel composed of whey proteins breaks down alcohol in the body and could reduce its harmful and intoxicating effects in humans.
Pro-Palestine protests extend to Basel and Fribourg universities
This content was published on
Demonstrators called for an academic boycott of all Israeli institutions and disassociation with Chaim Weizmann, the first Israeli president.
This content was published on
In many cases, China's use of AI undermines the national security of the US and its allies, according to a US government representative.
Swiss Hells Angels trial alleges rape and money laundering
This content was published on
An allegedly high-ranking member of the Hells Angels is accused of money laundering totalling millions and rape, among other serious crimes.
SWISS is airline ‘group flagship’ says Lufthansa boss
This content was published on
Despite challenges, Lufthansa and its most important subsidiary, Swiss International Airlines, promise increased satisfaction and continued growth.
Swiss rediscover communist zeal after 84-year hiatus
This content was published on
Over 300 participants founded the Revolutionary Communist Party (RKP) at its congress in Burgdorf in canton Bern at the weekend.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
How to solve the crisis of science
This content was published on
A leading public health expert tells swissinfo.ch how modern science can be put back on track for the greater good of society.
This content was published on
Nina Kathe has just started classes at the University of Zurich, but she’s already the author of award-winning research into a global health concern.
This content was published on
When Albert Einstein lived in Zurich, he used to prepare the groundwork for his revolutionary theories while sitting in a café. Many other Nobel Prize winners chose to spend time in the city for work, as an exhibition shows. A past laureate takes a guess at why.
Will exclusive collaborations yield more drug breakthroughs?
This content was published on
Recently FDA-approved, Novartis's pioneering immunotherapy was developed through an agreement with University of Pennsylvania researchers.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.